

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:  145372	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED  04/30/2026
NAME OF PROVIDER OR SUPPLIER  Pearl of Joliet, The		STREET ADDRESS, CITY, STATE, ZIP CODE  306 North Larkin Avenue Joliet, IL 60435	

For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)
<p>F 0686</p> <p>Level of Harm - Actual harm</p> <p>Residents Affected - Few</p> <p>Note: The nursing home is disputing this citation.</p>	<p>Provide appropriate pressure ulcer care and prevent new ulcers from developing.</p> <p><b>**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY**</b> Based on record review and interview, the facility failed to ensure a resident who was admitted with an unstageable pressure ulcer was seen by a wound care physician or nurse practitioner in a timely manner and failed to follow recommended wound treatment. This failure resulted in a resident (R1) to develop an infection in the wound and require surgical debridement. This applies to 1 of 3 residents (R1) reviewed for wound care in the sample of 3. The findings include: R1's electronic medical record (EMR) showed R1 was admitted to the facility on [DATE]. R1 was 75 years-old, who had multiple medical diagnoses including type 2 diabetes mellitus, pressure ulcer in the sacral region, hemiplegia and hemiparesis following cerebral infarction affecting left non-dominant side, necrotizing fasciitis, deep vein thrombosis, and hypothyroidism. On September 30, 2025, V3 (Wound Care Nurse) assessed R1 and noted R1 had an unstageable pressure ulcer to the sacral-coccyx area which measured as 1.5-centimeter (cm/centimeters) x 1.5 cm x 0 cm. (Length x Width x Depth). The wound surface was covered with slough and there was a moderate amount of serosanguinous exudate (drainage). This wound already existed prior to R1's admission to the facility. V3 noted the wound was clean, there was no odor, and no sign of infection. R1's Physician Order Summary (POS), dated September 29, 2025, shows R1 may be seen by a wound care physician. On September 30, 2025, the wound care treatment order showed: clean coccyx area, paint with skin prep, apply Medi honey, and fluff gauze, and cover with dry dressing three times a week and as needed. On November 19, 2025, the POS showed the wound treatment as : apply Dakin's (1/4 strength) External Solution to sacral wound topically one time a day from Monday through Friday for 14 days. On November 24, 2025, the POS showed the wound treatment as: apply Santyl External Ointment to sacral wound topically as needed. V3 continued to monitor and assess R1's wound and documented in the weekly wound assessment report. Assessments showed R1's wound remained unstageable; however, the wound size became bigger with each assessment. By November 1, 2025, the wound was measured as 4.3 cm x 3.80 cm. The wound was also noted with slight excoriation to surrounding wound bed which was fully covered with slough. The treatment administration record (TAR) for the month of November 2025, showed R1 continued to receive the same treatment of Medi honey three times a week. On November 5, 2025, V4's (Wound Specialist Nurse Practitioner/NP) documented R1 had an unstageable/unclassified pressure ulcer and has received a status of Not Healed. Upon initial wound encounter the wound measurements were 5.0 cm x 6.0 cm x 0.2 cm, with area of 30 square cm (cm<sup>2</sup>) and volume of 6 cubic cm (cm<sup>3</sup>). There was no tunneling, no sinus tract, and no undermining noted. There was a moderate amount of serosanguinous drainage, which has no odor. R1 reported wound pain of 0/10. The wound margin was attached to wound base. Wound bed has no granulation, it has 100% slough, no eschar and no epithelialization noted. The peri-wound color was normal. The temperature of the skin was within normal limits. The peri-wound did not exhibit signs and symptoms of infection. V4's recommended treatment was to clean the wound, apply Medi honey, calcium alginate, and cover with foam dry dressing three times a week and as needed. On November 8, 2025, V3's (Wound Care Nurse) documentation showed R1 was seen by V4 (Wound NP). Debridement procedure was discussed with V8 (R1's POA/Power of Attorney) and consent was obtained. Debridement was done to remove the (continued on next page)</p>

Any deficiency statement ending with an asterisk (\*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.

LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE	TITLE	(X6) DATE
---	-------	-----------

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:  145372	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED  04/30/2026
NAME OF PROVIDER OR SUPPLIER  Pearl of Joliet, The		STREET ADDRESS, CITY, STATE, ZIP CODE  306 North Larkin Avenue Joliet, IL 60435	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
<p>F 0686</p> <p>Level of Harm - Actual harm</p> <p>Residents Affected - Few</p> <p>Note: The nursing home is disputing this citation.</p>	<p>slough and necrotic tissue. Slight debridement was performed using a curette stick at R1's bedside. The area was scored using sharps with intent for better penetration of Medi honey. According to V3, this debridement procedure happened on November 5, 2025. On November 12, 2025, V4's (NP) wound note showed R1's laboratory result were reviewed. R1's WBC (White Blood Cell) was high. R1 was receiving an antibiotic for an UTI (Urinary Tract Infection). Sacral x-ray was reviewed; its depth was seen. Adherent slough has softened and liquified. Sacral wound was unstageable/unclassified pressure ulcer and has received a status of Not Healed. The subsequent wound encounter measurements are 5.5 cm x 5.5 cm x 1.5 cm., with an area of 30.25 sq cm and a volume of 45.375 cubic cm. There was no tunneling, no sinus tract, and no undermining noted. There was a moderate amount of serosanguinous drainage noted, which has no odor. R1 reported wound pain of 0/10 (no pain). Wound bed has no granulation, it has 100% slough, no eschar and no epithelialization noted. There was no change in the wound progression. The peri-wound skin texture, moisture, and color are all normal. The temperature of the peri-wound skin is within normal limits. Peri-wound skin does not exhibit signs and symptoms of infection. V4 performed a skin/tissue level excision/surgical debridement to R1's sacral pressure ulcer. On November 12m 2025, the recommended wound order was to cleanse the wound with Dakin's solution 1/4 strength, to apply Dakin's wet to moist gauze, and to cover wound with foam dressing. Dressing change were to be done daily and as needed. On November 19, 2025, V4's wound notes showed R1's sacral wound was now categorized as a stage 4 pressure injury/ pressure ulcer and had received a status of Not Healed. The subsequent wound encounter measurements are 6.5 cm x 4.5 cm x 2.0 cm, with an area of 29.25 sq cm and with a volume of 58.5 cubic cm. There was no tunneling, no sinus tract, and no undermining noted. There was a moderate amount of serosanguinous drainage, which has odor. R1 reported a wound pain of 0/10. Wound bed has no granulation, it has 100% slough, no eschar and no epithelialization noted. There was no change in the wound progression. The peri-wound skin texture, moisture, and color are all normal. Peri-wound skin presents with signs and symptoms of infection. The temperature of the peri-wound skin is within normal limits. This same note showed, V4 ordered wound C&amp;S (culture and sensitivity) and topical antibiotics. On November 19, 2025, the wound care order showed: cleanse wound with Dakin's solution 1/4 strength, apply Silvadene creme to wound, apply primary dressing calcium alginate, and cover with foam or dry dressing. The treatment and change of wound dressing were to be done daily and as needed.R1's wound culture results, dated November 23, 2025, showed R1 was positive for MRSA (Methicillin-resistant Staphylococcus aureus).On November 24, 2025, skin/wound notes showed the sacral wound culture result showed R1 was positive for MRSA. The wound was assessed; it was noted with black necrotic tissue and slightly odorous conclusive to necrotic tissue and active infection. Wound cleansed with Dakin's solution and treated as ordered. R1's Treatment Administration Record, dated November 2025, shows the following: On September 30, 2025: Clean coccyx area, paint with skin prep. Apply Medi Honey and fluff gauze and cover with dry dressing three times a week and prn (as needed). This order was d/c (discontinued) on November 19, 2025. On November 20, 2025: Clean coccyx area, paint with skin prep. Apply Medi-Honey, cover with fluff gauze, and cover with dry dressing three times a week and prn. This order was d/c on November 24, 2025. On November 20, 2025: Dakins (1/4 strength) External Solution. Apply to sacral wound topically once a day from Monday through Friday for 14 days. On November 22, 2025: Clean coccyx area, paint with skin prep, apply Medi honey and fluff gauze and cover with dry dressing 3x weekly and prn one time a day every Saturday and Sunday. This order was d/c on November 24, 2025. Hospital record showed R1 was admitted to the hospital on [DATE], and was discharged on December 5, 2025. History and physical, dated November 25, 2025, showed R1 was admitted to the hospital with worsening sacral pressure ulcer which was also positive for MRSA. The wound was noted with significant amount of necrotic tissue with foul smelling odor. This same hospital record showed a consultation note, dated November 25, 2025, which showed R1 had an infected sacral decubitus ulcer with osteomyelitis. On November 25, 2025, R1 underwent debridement procedure in the operating room (continued on next page)</p>		

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:  145372	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED  04/30/2026
NAME OF PROVIDER OR SUPPLIER  Pearl of Joliet, The		STREET ADDRESS, CITY, STATE, ZIP CODE  306 North Larkin Avenue Joliet, IL 60435	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
<p>F 0686</p> <p>Level of Harm - Actual harm</p> <p>Residents Affected - Few</p> <p>Note: The nursing home is disputing this citation.</p>	<p>due to diagnosis of infected stage 4 decubitus ulcer. Detailed description of the surgery showed excisional debridement of the skin, subcutaneous fat, muscle, and fascia of the decubitus ulcer. R1's MRI (Magnetic Resonance Imaging) of the sacrum, dated November 26, 2025, showed result of multiple impression including signs of osteomyelitis of the sacrococcygeal junction. On April 28, at 1:31 PM, V3 (Wound Care Nurse) stated R1 was admitted to the facility with unstageable pressure ulcer in the Sacro-coccyx area measuring 1.5 cm x 1.5 cm. R1's dressing change was three times a week every Monday, Wednesday, and Friday and as needed. The NP wound specialist (V4) visits once a week. V3 was unable to recall exact time when the wound started deteriorating, but that was when she called V4 to assess R1's wound. R1 was first seen on November 5, 2025, by V4. V4 debrided R1's pressure wound twice (November 5 and November 12, 2025). They were wondering why R1's wound continued to deteriorate and they tried to check all avenues to manage the wound. R1 had been off-loaded, she was turned side to side during incontinence care, she had the air mattress, the pressure relieving cushion in her wheelchair seat, and was given nutritional supplements as scheduled. R1 was debrided twice that's why the wound got bigger. The wound bed was covered with 80% soft necrotic and 20% slough. On April 29, 2026, at 4:11 PM, V3 stated the only time the treatment (Medi-honey) was changed when it was increased from three times a week to once daily and as needed. After the second debridement, it was changed to Santyl daily. The Medi honey was combatting the MRSA of the wound rather than the Silvadene. R1's wound was stable and was being treated. When V3 observed that the wound was deteriorating, that's when she recommended R1 to be seen by V4. On April 30, 2026, at 11:41 AM, V3 (Wound Nurse) said R1 received the first debridement procedure on November 5, 2025, and the second procedure on November 12, 2025. V3 usually receives verbal order from V4, and she recapped the order before V4 leaves the facility. V3 does not read V4's notes because it usually comes after two days. On April 29, 2026, at 10:16 AM, V4 (Nurse Practitioner/NP) stated when she first saw R1, she thought R1 was just recently admitted to the facility with community acquired pressure ulcer, because the size was big and it was unstageable. R1 had one pressure ulcer in the coccyx-sacral area. Upon her initial assessment, she observed R1 was receiving Medi honey and alginate treatment three times a week. R1 was a high risk for skin breakdown because she was not eating and she was non-compliant with repositioning and off-loading. The facility should have called for wound consultation right away when R1 was first admitted, because appropriate assessment and treatment could have been done sooner. V4 could have debrided the wound sooner by removing the dead tissues, so her wound could have had a higher chance of healing. V4 only ordered Dakin's solution treatment after the first debridement because it is a debriding agent and an antiseptic; it helps prevent infection. V4 ordered Dakin's solution and Silvadene ointment after the second debridement because she was worried about the potential infection. The Silvadene shield the wound from bacterial infection. V4 also said whatever she documented in the recommended treatment means that's what she ordered. If the Medi honey is not written in her notes that means it was discontinued. She ordered Dakin's to coccyx sacral wound daily and as needed. Treatment daily makes a big difference compared to three times a week. The Dakin's solution could have prevented the deterioration of the wound and potential infection. She reinforced to V3 the importance of the daily wound care to R1. V4 also stated all orders go under the primary care physician. As a wound consultant (NP) she can't enter her order directly into the facility's system, but she communicated with the wound care nurse her new wound care order or recommendation during the wound rounds. V4 gives verbal order to V3 and written report via email after her wound rounds containing her new wound treatment/care order, she does this before leaving the facility. Then V4 emails her completed wound notes after a day or two. The wound care nurse usually notifies the primary physician, and the primary physician usually approved V4's treatment recommendation. On April 29, 2026, at 1:17 PM, V7 (Primary Physician) stated he follows the recommendation of medical consultants because that's what they are here for. R1 was admitted with an unstageable pressure ulcer in the sacral-coccyx area. There was an admission order that R1 may (continued on next page)</p>		

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:  145372	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED  04/30/2026
NAME OF PROVIDER OR SUPPLIER  Pearl of Joliet, The		STREET ADDRESS, CITY, STATE, ZIP CODE  306 North Larkin Avenue Joliet, IL 60435	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
<p>F 0686</p> <p>Level of Harm - Actual harm</p> <p>Residents Affected - Few</p> <p>Note: The nursing home is disputing this citation.</p>	<p>be seen by a wound care physician. However, R1 was seen by a wound care specialist (V4) five weeks after she was admitted , after R1's wound continued to deteriorate. R1 received debridement procedure on November 12, and November 19, 2025. V4 gave an order to cleanse wound with Dakin's solution daily and as needed after the first debridement on November 5, and an order of Dakin's solution and Silvadene ointment daily and as needed after the second debridement was performed on November 19, 2025. However, R1's TAR showed that R1 continued to receive Medi honey treatment three times a week. Dakin's solution was applied to wound only on November 20, 21, and 24. There was no Silvadene treatment provided to R1. On November 19, V4 noted the foul odor from R1's wound, she ordered a wound culture, the result showed R1 was positive for MRSA. R1 was sent to the hospital after V8's (R1's POA) insistence where R1 was admitted for an infected stage 4 pressure ulcer with osteomyelitis and where she underwent surgical debridement. The Facility's Policy and Procedure for Wound Prevention and Healing with revision date of April 2026 shows:Intent: To provide wound care treatment/services (using a multidisciplinary approach) based on evidence-based standards of care under the direction of a physician.Procedure:Goal will focus on the clinical status of the wound, guide the appropriate intervention for the wound, indicate that, if there is no change in wound status within a pre-determined timeframe, re-assess and alter the plan, monitor and evaluate overall client outcomes (progression or regression), and determine the effectiveness of treatment. Continued/Ongoing Treatmenta. Nurse will provide wound care per physician orders and continue to implement and evaluate the plan of care based on the effectiveness of treatment. The nurse will notify the physician for any change in the patient's condition or lack of progress. d. If the patient is not responding to established treatment regimen, the Wound MD/NP shall evaluate the need for treatment change. Wound Care and Treatment:a. Wound care treatments are provided within an individualized plan of care under the direction of the physician.</p>		